Pseudomonas Aeruginosa Infections Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 12, 2018--The “Pseudomonas aeruginosa Infections - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Pseudomonas aeruginosa Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 7, 71, 22 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 15, 15 and 1 molecules, respectively.
Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Pseudomonas aeruginosa Infections - Overview Pseudomonas aeruginosa Infections - Therapeutics Development Pseudomonas aeruginosa Infections - Therapeutics Assessment Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development Pseudomonas aeruginosa Infections - Drug Profiles Pseudomonas aeruginosa Infections - Dormant Projects Pseudomonas aeruginosa Infections - Discontinued Products Pseudomonas aeruginosa Infections - Product Development Milestones Appendix
Companies MentionedAchaogen Inc Acies Bio doo Aeolus Pharmaceuticals Inc AiCuris GmbH & Co KG AlgiPharma AS AmpliPhi Biosciences Corp Appili Therapeutics Inc Aridis Pharmaceuticals Inc AstraZeneca Plc Daiichi Sankyo Co Ltd Destiny Pharma Plc Evaxion Biotech ApS Evotec AG F. Hoffmann-La Roche Ltd Helix BioMedix Inc Inhibrx LP Insmed Inc KBP BioSciences Co Ltd Kyorin Pharmaceutical Co Ltd Lakewood-Amedex Inc LegoChem Biosciences Inc Meiji Seika Pharma Co Ltd Melinta Therapeutics Inc Microbiotix Inc Nosopharm SAS Novabiotics Ltd Novartis AG Peptilogics Inc Pfizer Inc Pherecydes Pharma SA Phico Therapeutics Ltd Redx Pharma Plc Sealife PHARMA GMBH Visterra Inc Wockhardt Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sdvssl/pseudomonas?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181012005119/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/12/2018 05:16 AM/DISC: 10/12/2018 05:16 AM